Login / Signup

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.

Ian N BruceRichard A FurieEric F MorandSusan ManziYoshiya TanakaKenneth C KalunianJoan T MerrillPatricia PuzioEmmanuelle MahoChristi KleoudisMarius AlbulescuMicki HultquistRaj Tummala
Published in: Annals of the rheumatic diseases (2022)
NCT02446912 and NCT02446899.
Keyphrases
  • clinical trial
  • systemic lupus erythematosus
  • disease activity
  • phase ii
  • double blind
  • study protocol
  • phase iii
  • randomized controlled trial
  • rheumatoid arthritis